Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E. Merryman RW, et al. Among authors: cashen a. Blood Adv. 2020 Mar 10;4(5):858-867. doi: 10.1182/bloodadvances.2019001355. Blood Adv. 2020. PMID: 32126141 Free PMC article.
Therapy of relapsed Hodgkin lymphoma.
Cashen AF, Bartlett NL. Cashen AF, et al. Blood Rev. 2007 Sep;21(5):233-43. doi: 10.1016/j.blre.2007.06.001. Epub 2007 Aug 1. Blood Rev. 2007. PMID: 17683834 Review.
Salvage regimens for Hodgkin lymphoma.
Cashen AF, Bartlett NL. Cashen AF, et al. Clin Adv Hematol Oncol. 2008 Jul;6(7):517-24. Clin Adv Hematol Oncol. 2008. PMID: 18654119 Review.
Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, Dipersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA. Smeltzer JP, et al. Among authors: cashen af. Biol Blood Marrow Transplant. 2011 Nov;17(11):1646-52. doi: 10.1016/j.bbmt.2011.04.011. Epub 2011 May 3. Biol Blood Marrow Transplant. 2011. PMID: 21601641 Free PMC article.
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD. Fowler N, et al. Among authors: cashen af. J Clin Oncol. 2011 Sep 1;29(25):3389-95. doi: 10.1200/JCO.2010.32.1844. Epub 2011 Aug 1. J Clin Oncol. 2011. PMID: 21810687 Clinical Trial.
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL. Fehniger TA, et al. Among authors: cashen af. Blood. 2011 Nov 10;118(19):5119-25. doi: 10.1182/blood-2011-07-362475. Epub 2011 Sep 21. Blood. 2011. PMID: 21937701 Free PMC article. Clinical Trial.
156 results